Want to see SE:XBRANE full AI Analyst Report?
Top Page
Xbrane Biopharma AB
(XBRANE)
Select Model
Select Model
Rating:54Neutral
Price Target:
kr13.50
▲(30.18% Upside)
Action:Reiterated
Date:10/30/26
The score is held back primarily by weak financial performance—persistent operating losses and substantial negative operating/free cash flow—despite a relatively supportive, low-leverage balance sheet. Technicals provide a meaningful offset with a clear uptrend and positive momentum. Valuation contributes only modestly because the negative P/E reflects ongoing losses and there is no dividend yield support.
Positive Factors
Low Leverage
The comparatively low leverage and sizable equity base provide financial resilience for a biotechnology company funding development programs. This reduces immediate debt pressure and preserves more flexibility to support operations, partnerships, and commercialization while the pipeline develops.
Negative Factors
Persistent Cash Burn
Deeply negative operating and free cash flow shows that the business is not yet self-funding its operations and investments. Continued cash consumption can require financing or use of balance-sheet resources, limiting flexibility and increasing execution pressure over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
The comparatively low leverage and sizable equity base provide financial resilience for a biotechnology company funding development programs. This reduces immediate debt pressure and preserves more flexibility to support operations, partnerships, and commercialization while the pipeline develops.
Read all positive factors
Xbrane Biopharma AB (XBRANE) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr267.87M
Dividend YieldN/A
Average Volume (3M)102.30K
Price to Earnings (P/E)―
Beta (1Y)0.51
Revenue Growth-68.66%
EPS Growth-137.27%
CountrySE
Employees29
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.40
Shares Outstanding20,605,349
10 Day Avg. Volume197,036
30 Day Avg. Volume102,299
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)27.69
Price to Sales (P/S)101.88
P/FCF Ratio-39.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.94
Revenue Forecast (FY)kr180.00M
Xbrane Biopharma AB Business Overview & Revenue Model
Company Description
Xbrane Biopharma AB (publ) is a biotechnology firm, founded in 2008 and based in Solna, Sweden, that specializes in the creation, manufacturing, and distribution of biosimilar medications. The company's development pipeline includes Xlucane, a ran...
How the Company Makes Money
Xbrane makes money primarily through biosimilar-related commercialization and partnering economics. Key revenue streams can include: (1) Net sales/royalties and related commercial income from biosimilar products where Xbrane has a commercial inter...
Xbrane Biopharma AB Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 83.30M | 152.35M | 198.70M | 238.73M | 57.62M | 11.53M |
| Gross Profit | -5.12M | 74.94M | 180.47M | 35.39M | 41.04M | -684.00K |
| EBITDA | -60.62M | -16.50M | -181.97M | -282.03M | -149.34M | -168.37M |
| Net Income | -75.00M | 127.24M | -266.22M | -388.17M | -172.23M | -191.01M |
Balance Sheet | ||||||
| Total Assets | 642.61M | 671.62M | 842.43M | 653.51M | 690.51M | 688.43M |
| Cash, Cash Equivalents and Short-Term Investments | 49.50M | 86.59M | 124.33M | 65.40M | 193.99M | 295.18M |
| Total Debt | 63.71M | 58.31M | 191.72M | 231.48M | 38.22M | 44.38M |
| Total Liabilities | 103.76M | 110.97M | 633.89M | 482.17M | 265.63M | 256.69M |
| Stockholders Equity | 538.85M | 560.65M | 208.54M | 171.34M | 424.89M | 431.74M |
Cash Flow | ||||||
| Free Cash Flow | -141.35M | -390.33M | -185.97M | -423.45M | -254.04M | -296.96M |
| Operating Cash Flow | -130.31M | -250.69M | -133.73M | -406.68M | -193.92M | -219.61M |
| Investing Cash Flow | -85.17M | -37.14M | -52.25M | -16.77M | -60.13M | -77.35M |
| Financing Cash Flow | 263.19M | 255.60M | 243.62M | 298.70M | 148.86M | 349.37M |
Xbrane Biopharma AB Technical Analysis
Positive
10.37
Price Trends
11.27
Positive
10.80
Positive
9.91
Positive
Market Momentum
0.85
Negative
51.58
Neutral
48.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XBRANE, the sentiment is Positive. The current price of 10.37 is below the 20-day moving average (MA) of 12.95, below the 50-day MA of 11.27, and above the 200-day MA of 9.91, indicating a bullish trend. The MACD of 0.85 indicates Negative momentum. The RSI at 51.58 is Neutral, neither overbought nor oversold. The STOCH value of 48.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:XBRANE.
Xbrane Biopharma AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | kr471.41M | 2.46 | 63.09% | ― | ― | ― | |
55 Neutral | kr4.00B | -5.01 | ― | ― | -3.57% | 8.84% | |
54 Neutral | kr267.87M | -5.42 | -13.41% | ― | -68.66% | -137.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | kr182.86M | -7.75 | -56.09% | ― | ― | 14.10% | |
43 Neutral | kr375.74M | -0.77 | -128.54% | ― | -87.22% | -70.29% | |
39 Underperform | kr35.68M | -0.01 | -439.98% | ― | -99.33% | 64.90% |
* Healthcare Sector Average
SE:XBRANE
Xbrane Biopharma AB
13.00
2.30
21.50%
SE:HNSA
Hansa Biopharma AB
39.34
8.14
26.09%
SE:ATORX
Alligator Bioscience AB
0.01
-0.30
-96.77%
SE:BINV
BioInvent International AB
5.71
-26.14
-82.07%
SE:ELIC
Elicera Therapeutics AB
2.74
-3.28
-54.49%
SE:CANTA
Cantargia AB
1.67
-1.84
-52.36%
Xbrane Biopharma AB Corporate Events
Xbrane Builds Biosimilars Momentum with FDA Nod and Growing European Sales
Oct 30, 2026
Xbrane reported third-quarter 2026 revenue of SEK 54.8 million, driven almost entirely by European sales of Ximluci, and an EBITDA loss of SEK 6.6 million, reflecting continued investment in RD that accounted for 43 percent of operating costs. Cas...
Xbrane Wins FDA Nod for Lucamzi Biosimilar to Lucentis
Oct 27, 2026
The U.S. Food and Drug Administration has approved Lucamzi, Xbrane Biopharma’s ranibizumab biosimilar to Lucentis, clearing the way for a U.S. launch in 2027 in partnership with commercialization allies. The decision follows extensive analyt...
Xbrane Biopharma to Present Q3 2026 Interim Results Amid Biosimilar Expansion
Oct 23, 2026
Xbrane Biopharma AB, a Stockholm-based biotech focused on cost-efficient biosimilar drugs, is building a portfolio of candidates that target reference products with an estimated EUR 23 billion in annual peak sales. Its lead product Ximluci, a bios...
Xbrane Reaches Key Milestone as Xdivane Pivotal Trial Fully Enrolls Melanoma Patients
Oct 13, 2026
Xbrane Biopharma AB and its strategic partner Intas Pharmaceuticals have completed patient recruitment for the pivotal clinical trial of Xdivane™, a biosimilar candidate to Bristol Myers Squibb’s blockbuster oncology drug Opdivo® ...
Xbrane Biopharma Sets Nomination Committee Ahead of 2027 AGM
Oct 9, 2026
Xbrane Biopharma AB, a Swedish biotech specializing in cost-efficient biosimilar development, is building a portfolio of biological drugs targeting multi-billion-euro reference markets, with its lead product Ximluci® already authorized and la...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.